LLY's 2011Zyprexa expiry vs. PFE's Lipitor expiration
Here is an excerpt from your post: "You assign WAY too much weight to "an exciting new blockbuster or two." Pfizer has had no fewer than THREE such drugs in the last couple of years - Lyrica, Chantix and Sutent. How much good has this done for the stock price?" However you forgot that during these last couple of years, we have been witness to the torcetrapib and Exubera flops that cost PFE many millions of dollars. Torcetrapib was an internal flop and Exubera was a purchased flop that cost the company 2 billion dollars. Evidently these two gigantic flops had a much more negative impact on PFE's image than the success of Lyrica, Chantix, and Sutent. There is still the perception among analysts and stockholders that PFE is not nearly as savvy as pharmas such as Merck in developing new drugs. I am aware of PFE's recent claim of all the promising drugs that they now have in middle and last stage development. We are all waiting with bated breath to see if PFE can successfully bring some of these drugs to market in a timely fashion. If the company proves to all of us that it can succesfully comercialize these products, the PFE stock price will indeed go up. If not, the PFE stock price will continue to flounder as it has been doing over the last few years. The time has come for PFE to either put up or continue to suffer the consequences!